triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 600 participants.

Also called NCT07440381

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07440381
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07440381. Randomized; no masking; primary purpose treatment. Start 2026-09 (anticipated); primary completion 2027-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE
Acronym
PERSUADE
Condition
Acute Coronary Syndromes
Condition
Secondary Prevention
Condition
Lipids
Intervention (Drug)
Triple oral lipid lowering treatment
Lead sponsor
Heart Care Foundation (class: other)
Collaborator
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (class: industry)

Record details

Record id
cardio:ct-nct07440381
Content hash
41a5548a0f4df68fedfd66ea1b14068a2c9c73ce729058bab433e1a1ea13e989